About this episode

The episode discusses the frontMIND trial and its implications for treating DLBCL with tafasitamab.

Episode Overview For the second time in two decades, a phase 3 trial has shown a statistically significant improvement over R-CHOP in newly diagnosed diffuse large B-cell lymphoma (DLBCL). In this episode, Eddie, Raj, and Ashwin sit down with Professor Charles Herbaux to unpack the data, debate the clinical implications, and ask the question that's on every hematologist's mind: is this enough to change practice? Background: Setting the Stage for Tafasitamab Before diving into frontMIND, the episode provides context on tafasitamab , a CD19-targeting monoclonal antibody L-MIND (Phase 2 — relapsed/refractory DLBCL): 81 patients with R/R DLBCL ORR 58%, complete response rate 41% Established activity of tafasitamab + lenalidomide in the relapsed setting https://pubmed.ncbi.nlm.nih.gov/32511983/ First-MIND (Phase 1b — frontline DLBCL, IPI 2–5): 66 patients randomized: tafa-R-CHOP (n=33) vs. tafa-len-R-CHOP (n=33) ORR: 75.8% vs. 81.8%, respectively Serious treatment-emergent adverse events: 42.4% vs. 51.5% Provided the signal (and the safety caution) to move to phase 3 https://pubmed.ncbi.nlm.nih.gov/37369099/ The frontMIND Trial Design: Phase 3, double-blind, placebo-controlled…

People in this episode

Hosts: Eddie, Raj, Ashwin

Guest: Dr. Charles Herbaux

Topics covered

• DLBCL
• clinical trials
• hematology
• monoclonal antibodies
• treatment advancements

Mentioned in this episode

Organizations: R-CHOP

Products: tafasiitamab, lenalidomide

Explore listener stats, chart rankings, contacts and more on the Blood Cancer Talks podcast page.